Screening and diagnosis of sarcopenia in rheumatic and musculoskeletal diseases: findings from a cross-sectional study
Authors:
- Eleni C. PardaliEPEleni C. Pardali
- Katerina-Maria KontouliKKKaterina-Maria Kontouli
- Arriana GkouviAGArriana Gkouvi
- Irene A. TsakmakiITIrene A. Tsakmaki
- Eleni PatrikiouEPEleni Patrikiou
- Maria KarapliMKMaria Karapli
- Christos LiaskosCLChristos Liaskos
- Nektarios Marios LiapisNLNektarios Marios Liapis
- Vasiliki SyrmouVSVasiliki Syrmou
- Ioannis AlexiouIAIoannis Alexiou
- Theodora SimopoulouTSTheodora Simopoulou
- Sousana K. PapadopoulouSousana K. Papadopoulou
Open Access
- 28 February 2025
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 45 (3) , 1-10
Abstract
Sarcopenia is characterized by loss of muscle mass and reduced muscle function, presenting various adverse events, especially when inflammation is present. The present study aimed to determine the prevalence of sarcopenia and sarcopenic obesity among patients with rheumatic and musculoskeletal diseases (RMDs) and identify the risk for sarcopenia using two screening tools the Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) and the Mini Sarcopenia Risk Assessment (MSRA). In this single-center cross-sectional study, 220 consecutive patients visiting the Department of Rheumatology and Clinical Immunology at the University General Hospital of Larissa were interviewed. The EWGSOP criteria were used for the diagnosis of sarcopenia, while sensitivity, specificity, positive predictive values, number needed to screen, and positive and negative likelihood ratios were used to validate the diagnostic validity of the SARC-F and the MSRA. Univariate and multivariate logistic regression analyses were also applied to model the relationship between sarcopenia and other variables. In the total sample, 15.9% of patients were diagnosed with sarcopenia and one patient with sarcopenic obesity. The SARC-F (sensitivity 22.2%, specificity 75.6%), the 5-item (sensitivity 88.9%, specificity 18.9%), and the 7-item MSRA (sensitivity 91.7%, specificity 9.2%) presented poor clinical performance when used for screening alone. Univariate logistic regression analyses showed that underweight status, systemic sclerosis and appetite loss are strong contributors to sarcopenia diagnosis. Sarcopenia is prevalent among RMDs, and screening is essential within RMD clinics. None of the screening tools (SARC-F and MSRA) can stand alone in assessing sarcopenia in patients with RMDs. More research is required to understand sarcopenia in RMDs and validate the wide-using screening tools.Keywords
This publication has 52 references indexed in Scilit:
- SARC-F: A Simple Questionnaire to Rapidly Diagnose SarcopeniaJournal of the American Medical Directors Association, 2013
- Corticosteroids and muscle wasting: role of transcription factors, nuclear cofactors, and hyperacetylationCurrent Opinion in Clinical Nutrition and Metabolic Care, 2010
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases, 2007
- Greek Orthodox fasting rituals: a hidden characteristic of the Mediterranean diet of CreteBritish Journal of Nutrition, 2004
- Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventionsRheumatology, 2004
- Fat-free mass index and fat mass index percentiles in Caucasians aged 18–98 yInternational Journal of Obesity, 2002
- Lactose malabsorption in Greek adults: correlation of small bowel transit time with the severity of lactose intolerance.Gut, 1982
- Generalized equations for predicting body density of womenMedicine & Science in Sports & Exercise, 1980
- Generalized equations for predicting body density of menBritish Journal of Nutrition, 1978